The study established and validated a seven-gene signature comprising METTL3, COL18A1, NASP, PHLPP2, TIMP1, U2AF2, and VEGFA, with a good capability for predicting glioma survival. These genes were identified to influence 81 anticancer drug responses, which further contributes to the early-phase clinical trials of drug development. Here, METTL3 is linked to central nervous system cancer.